Joonghun Pharmaceutical Has Launched Artgaon to Compete With Top European Fillers
30.3.2021 12:00:00 EEST | Business Wire | Press release
Joonghun Pharmaceutical has officially launched their premium cross-linked hyaluronic acid dermal filler, Artgaon.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210330005456/en/
Joonghun Pharmaceutical has officially launched their premium cross-linked hyaluronic acid dermal filler, Artgaon (Photo: Business Wire)
Artgaon, with its certification of the CE mark, is specifically aimed to target the European aesthetic market as its slogan states “The Finest, for European Professionals”. Joonghun Pharmaceutical is a pharmaceutical company in South Korea that specializes in Hyaluronic Acid Injections used in orthopedic treatments for 15 years. With their in-depth knowledge of HA characteristics, they were able to develop a dermal filler designed to compete against the top European brands in the aesthetics industry.
According to Dr. YeoHye Yoon, the Quality Director from Joonghun, the main vision for Artgaon during its product development was to provide a new aesthetic experience like no other for both the patient and practitioner. To deliver this experience, Artgaon was focused on two things: high quality and unique cross-linking technology.
Artgaon is manufactured under strict pharmaceutical guidelines despite dermal fillers being classified as medical devices. “This commitment enables us to have higher standards of safety for every component of the filler. For example, Artgaon is manufactured in cleanrooms that control particles as small as 10-micrometers. Naturally, this makes Artgaon extremely clean, which we believe would add to the confidence of doctors using our product.”
Artgaon’s unique cross-linking technology allows doctors to enjoy an injection force of a mere 7-8 newtons that is smooth and consistent. Despite this, Artgaon boasts high elastic (G prime) and cohesive properties when inside the skin. Joonghun claims that their formula for Artgaon shows natural results not only by looks but by experiences felt by patients as well. “Artgaon really allows the doctor to mold the beauty they want for their patients due to the low injection force coupled with high molding capabilities.”
The gel characteristics of Artgaon is to be expressed in their soon to be updated package designs. “Artgaon’s new package designs are based on the architectural structure of the industrial era, which remain firm and capture beauty even to this day. We wanted this architectural beauty from the industrial era to represent Artgaon’s gel structure; to be firm and attain its beauty even over time.”
The quality and performance of Artgaon has already surprised doctors who have tested Artgaon. It is only a matter of time until Artgaon disrupts the beauty market of Europe and the world.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210330005456/en/
Contact information
Tulay Genc | info@b2press.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FERM FOOD Acquires Orkla’s Former Site and Scales Up: Up to 20,000 Tonnes of Fermented Ingredients Per Year11.3.2026 08:00:00 EET | Press release
Danish ingredient producer FERM FOOD is acquiring Orkla’s former manufacturing site in Skovlund, Denmark, effective 1 April 2026. The acquisition provides new production facilities to expand the output of fermented plant-based ingredients for the food industry — driven by export demand that has emerged faster than expected. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260310904877/en/ Jens Legarth (CEO), Rikke Matthiesen (CSO), and Torbjørn Tyndkjær-Thomsen (Food & Process Developer) at FERM FOOD’s new production facilities. “We have outgrown our current facilities. With the Skovlund site, we can supply many more food manufacturers in Denmark and abroad. Global interest has developed faster than we expected — and that is why we are scaling up now,” says Jens Legarth, CEO of FERM FOOD. Once fully ramped up, the new fermentation facility is expected to reach an annual capacity of up to 20,000 tonnes, depending on product mix
Galderma Buys Back Shares Worth CHF 232 Million in the Context of Accelerated Bookbuild Offering11.3.2026 08:00:00 EET | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that it has agreed to repurchase 1.6 million shares at a price of CHF 143.75 per share for a total consideration of CHF 232 million in the context of the accelerated bookbuild offering (“ABO”) of Galderma shares by Sunshine SwissCo GmbH (“EQT”), Abu Dhabi Investment Authority (Private Equities Department) and Auba Investment Pte. Ltd. (all together the “Selling Shareholders”) launched yesterday evening. The repurchase was made at the same price per share determined by the bookbuilding offering. As a result of yesterday evening’s ABO, the Selling Shareholders have fully divested their remaining stake in Galderma. The repurchase, which is expected to settle on March 13 is being financed by Galderma’s existing liquidity on hand and will not affect the company’s ability to deliver on its strategic and financing priorities. The shares will be held in treasury for future use in connection with Galderma's employe
Thales Launches SkyDefender: The Integral Air and Missile Defence Dome With Artificial Intelligence11.3.2026 08:00:00 EET | Press release
As air and missile threats are evolving faster than ever, from slow-moving drones to hypersonic missiles, attacks are becoming increasingly complex, saturating and unpredictable. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260310398606/en/ SkyDefender © Thales Thales SkyDefender provides full protection against all types of air threats, from a few kilometres to several thousands of kilometres: Short-range: for protection of forces, vital assets and sensitive sites: ForceShield creates a real protection bubble against lower layer and surface threats at very short- and short-range, such as drones. Medium-range: for protection at theatre-level defence: SAMP-T NG by eurosam1 with up to 150 km engagement range, including Thales’ powerful Ground Fire radar with 350 km range and 360°/90° coverage against medium-range defence. Long-range: for protection against long-range threats with early-warning capabilities: a unique capacity
Curatis and Neupharma Announce Exclusive Licensing Agreement to Develop and Market Corticorelin (C-PTBE-01) for the Treatment of Peritumoral Brain Edema in Japan11.3.2026 08:00:00 EET | Press release
Curatis Holding AG (SIX: CURN) and Neupharma Co., Ltd. (“Neupharma”), a Japanese pharmaceutical company specializing in oncology, immunology, pulmonology and cardiology disorders, today announce an exclusive license and development agreement for corticorelin (C-PTBE-01) in Japan. Under the terms of the agreement, Neupharma will receive exclusive rights to develop and commercialize corticorelin for the treatment of peritumoral brain edema (PTBE) in Japan. PTBE is a tumor-associated condition for which no approved targeted therapies currently exist. Neupharma will finance and conduct a pivotal clinical trial in Japan to support filing for approval in Japan. Curatis will receive upfront and milestone payments for the achievement of regulatory and commercial targets totaling up to CHF 83.5 million, as well as royalties on future sales in Japan of up to 20%. The agreement stipulates that corticorelin is planned to be introduced in Japan initially for children and adolescents. A meeting with
Galderma Completes Successful Placement of EUR 500 Million Eurobond11.3.2026 07:55:00 EET | Press release
Galderma Group AG (SWX:GALD): NOT FOR DISTRIBUTION IN THE UNITED STATES OR IN ANY OTHER JURISDICTION IN WHICH SUCH DISTRIBUTION WOULD BE RESTRICTED BY APPLICABLE LAW OR REGULATION. Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced the successful placement of a single-tranche EUR 500 million Eurobond. The bond has a 5-year maturity and carries a fixed-rate annual coupon of 3.375%. The Eurobond was placed on March 10, 2026, with settlement expected on March 17, 2026, and will be listed on the SIX Swiss Exchange. Citigroup, ING, J.P. Morgan and RBC Capital Markets jointly led the transaction. Net proceeds from the transaction will be used to fully repay Galderma’s existing bank term loan issued in connection with the company’s initial public offering in March 2024. The transaction represents the final step in Galderma’s refinancing process, having obtained two investment grade credit ratings. Galderma is currently rated ‘BBB’ (stable outlook) by Fitc
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom